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Introduction: Tuberculous meningitis is a frequent extrapulmonary disease caused by Mycobacterium tuberculosis
and is associated with high mortality rates and severe neurological sequelae. In an earlier study employing DNA
microarrays, we had identified genes that were differentially expressed at the transcript level in human brain tissue
from cases of tuberculous meningitis. In the current study, we used a quantitative proteomics approach to discover
protein biomarkers for tuberculous meningitis.
Methods: To compare brain tissues from confirmed cased of tuberculous meningitis with uninfected brain tissue,
we carried out quantitative protein expression profiling using iTRAQ labeling and LC-MS/MS analysis of SCX
fractionated peptides on Agilent’s accurate mass QTOF mass spectrometer.
Results and conclusions: Through this approach, we identified both known and novel differentially regulated
molecules. Those described previously included signal-regulatory protein alpha (SIRPA) and protein disulfide
isomerase family A, member 6 (PDIA6), which have been shown to be overexpressed at the mRNA level in
tuberculous meningitis. The novel overexpressed proteins identified in our study included amphiphysin (AMPH) and
neurofascin (NFASC) while ferritin light chain (FTL) was found to be downregulated in TBM. We validated
amphiphysin, neurofascin and ferritin light chain using immunohistochemistry which confirmed their differential
expression in tuberculous meningitis. Overall, our data provides insights into the host response in tuberculous
meningitis at the molecular level in addition to providing candidate diagnostic biomarkers for tuberculous
meningitis.
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Tuberculosis (TB) is a common and sometimes fatal
transmissible disease, especially in developing countries.
Approximately thirty percent of the global population is
exposed to the acid-fast bacilli causing TB. Of those who
are infected with tuberculosis, ~10% percent develop a
clinical manifestation of the disease during their lifetime.
From a global perspective, approximately twenty percent
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reproduction in any medium, provided the orHealth Organization (WHO) has estimated that one
million children develop TB annually worldwide which
accounts for about 11% of all TB cases [1]. Tuberculous
bacilli most commonly infect lungs. Mycobacterium
tuberculosis (MTB) may also spread to extrapulmonary
sites including the meninges, lymph nodes, genitourinary
tract, skeletal system and skin [2]. Tuberculous meningi-
tis (TBM) is the infection of meninges caused by MTB,
with a mortality rate of ~30%. Further, those who survive
TBM are usually left with severe neurological defects
[3-5]. There is an increased risk of TBM in HIV-infected
patients as compared to non-HIV infected cases although
the clinical manifestations of the disease do not differ
between the two groups [6,7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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logical examination is considered a gold standard for the
diagnosis of TBM. However, this method is time con-
suming and insensitive, with a positive outcome achieved
only in 25–70% of clinically diagnosed cases [8]. Al-
though PCR assays can be an alternative rapid approach
for diagnosis, they cannot differentiate between latent or
active forms of the disease. Although nucleic acid ampli-
fication test (NAAT) has a high specificity when tested
in body fluids, it lacks adequate sensitivity in cases of
meningitis and pleuritis [9].
Amongst the existing molecular markers, Adenosine
deaminase isoenzyme-2 (ADA2) has a sensitivity of 100%
and a specificity of 86.4% for the detection of TBM in
cerebrospinal fluid (CSF) [10]. Adenosine deaminase
(ADA) activity in the CSF of TBM patients has been sug-
gested to be useful for early differential diagnosis of TBM
[11]. The ADA activity of CSF and plasma have been
evaluated as a diagnostic aid in TBM [12] and ADA
activity in CSF was considered to be a simple, useful and
rapid diagnostic test for early recognition of TBM in
children [13]. However, overexpression of ADA was also
often overexpressed in other forms of meningitis includ-
ing infections with pyogenic bacteria [14]. In the CSF of
TBM patients, the presence of 65 kDa heat shock protein
antigen might be a marker for early diagnosis of the dis-
ease [15]. High levels of CSF lactate and lactate dehydro-
genase levels have also been suggested for diagnosing
TBM [16].
Early diagnosis of TBM is considered a key to effective
treatment and prognosis. Approximately 90% of the
patients are diagnosed in stage II or III [17]. Overall, the
diagnosis of TBM still remains a major challenge due to
inadequate current diagnostic methods and poor sensi-
tivity and/or specificity of existing markers. Although
corticosteroids are used extensively to reduce mortality
and neurological disability, it may not be the only solu-
tion to reduce the mortality and morbidity [18]. In TBM,
a number of pathological changes including meningeal
adhesion, infarction, tuberculoma and hydrocephalus may
occur leading to neurological sequelae [4]. These sequelae
are known to correlate with the stage of meningitis
at admission. Patients treated at an early stage have a
five times higher chance of recovery than those with
advanced disease stages [19]. Therefore, patient’s clinical
condition at admission and delay in starting the treat-
ment are important factors for determining their survival
[20]. These findings emphasize the need to focus on iden-
tifying candidate molecular markers which can be devel-
oped as diagnostic tools in the management of TBM.
Mass spectrometry-based quantitative proteomics has
emerged as a powerful approach for identifying and
studying disease biomarkers and has become one of the
essential tools in biomarker discovery [21,22]. Advancesin quantitative mass spectrometry have led to identifica-
tion and quantitation of biomarkers which serve as
indicators of disease progression, prognosis, drug safety
and help to elucidate the mechanism of drug treatment
[23]. There are various labeling approaches that one
can employ to carry out quantitative proteomic mea-
surements. In vitro labeling methods include Isobaric
Tags for Relative and Absolute Quantitation (iTRAQ),
Isotope-Coded Affinity Tags (ICAT), 18O labeling and
in vivo methods include Stable Isotope Labeling by
Amino acids in Cell culture (SILAC) and 15Nlabeling
[24,25]. iTRAQ labeling is an effective method for
studying differential protein expression levels in tissue
samples. It has been extensively used for biomarker
discovery in various disease contexts [26-34].
In this study, we used an iTRAQ-based quantitative
proteomic approach to identify differentially expressed
proteins from brain tissues of tuberculous meningitis
cases as compared to controls. We identified several pro-
teins which are differentially expressed in TBM. These
proteins include both novel and previously reported can-
didate protein markers. We validated some of these can-
didate biomarkers using immunohistochemical labeling.Materials and methods
Sample collection
The study was approved by scientific ethics committee
of National Institute of Mental Health and Neuro
Sciences (NIMHANS), Bangalore, India. Samples from
frontal cortex with overlying meninges from cases of tu-
berculous meningitis (n=6) and similar, but uninfected,
control brain tissues (n=6) from victims of road traffic
accidents were collected at the time of autopsy. The
autopsy was conducted within 8–16 h postmortem with
the body kept at 4°C after death. The samples were
obtained from the Human Brain Tissue Repository,
Department of Neuropathology, NIMHANS, Bangalore.
Sample details including the selection criteria are pro-
vided in Additional file 1: Table S1.Sample preparation and iTRAQ labeling
Brain tissue samples were lysed in 0.5% SDS, sonicated,
homogenized and centrifuged at 13,000 rpm for 10 min
at 4°C. Supernatant was collected and protein quantita-
tion was carried out by Lowry’s assay (Bio-Rad Hercules,
CA; USA). For each condition, 160 μg of protein sample
was utilized for the experiment. Each sample was treated
with 4 μL of reducing agent (tris (2-carboxyethyl) phos-
phine (TCEP)) at 60°C for 1 h and alkylated with 2 μL of
cysteine blocking reagent, methyl methanethiosulfonate
(MMTS) for 10 min at room temperature. After alkyl-
ation, the samples were subjected to trypsin digestion
(Sequencing Grade Modified Trypsin, Promega Cat#:
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ples from each condition was split in equal halves (80 μg
each) and labeled with iTRAQ 4-plex reagents (catalog #
4352135, Applied Biosystems, Foster City, CA, USA) as
per manufacturer’s protocol. We used technical repli-
cates for control and TBM samples. Peptides from con-
trol samples were labeled with iTRAQ reagents yielding
reporter ions 114 and 115 while peptides from TBM
were labeled with 116 and 117. The samples were pooled
following iTRAQ labeling.Strong cation exchange chromatography (SCX)
Pooled iTRAQ labeled peptides were fractionated by strong
cation exchange chromatography on PolySULFOETHYL A
column (200 x 2.1 mm; 5 μm; 200Å PolyLC, Columbia,
MD) using Agilent’s 1200 series HPLC system. The pep-
tides were reconstituted in SCX solvent A (10 mM potas-
sium phosphate, 25% acetonitrile, pH 2.8) and loaded
on SCX column isocratically using 100% solvent A for
20 min at a flow rate of 200 ul per minute. Peptides were
eluted using a 30 min gradient from 8% to 35% solvent B
(350 mM KCl in solvent A). Fractions were collected
every minute using a fraction collector. The fractions
were vacuum dried and stored at −80°C until LC-MS/MS
analysis.LC-MS/MS analysis
The samples were analyzed on HPLC chip-cube inter-
faced with Accurate Mass 6520 quadrupole time of flight
mass (QTOF) spectrometer (Agilent Technologies, Santa
Clara, CA). The HPLC-Chip contains a 40 nl enrichment
column and 43 mm x 75 um analytical column. These
columns were made up of a reversed-phase material
Zorbax 300SB-C18, with a particle size of 5 μm. The
samples were loaded onto the enrichment column using
Agilent’s 1200 series capillary liquid chromatography
pump at a flow rate of 3 μl/min using 97% solvent A
and 3% solvent B. An injection flush volume of 4 μl was
applied during enrichment step. The peptides were
eluted at a flow rate of 400 nl/min using a gradient of
solvent A (0.1% formic acid) and solvent B (0.1% formic
acid in 90% acetonitrile). The gradient was started from
3% to18% of solvent B over 8 min, subsequently changed
to 22% B in the next 7 min and finally changed to 45%
of solvent B for 25 min. MassHunter workstation data
acquisition software (Version B.01.03) was used for data
dependent acquisition. MS spectra were acquired for
1 second from m/z 350–1800 followed by three MS/MS
spectra in next second comprising the duty cycle of
2.1 second including an interscan delay of 0.1 second.
Precursor ions were preferred based on charge state in
the order of 2+, 3+ and >3+. The capillary and fragmen-
tor voltage of 1950V and 175 V respectively was appliedwith a medium isolation width of 4 m/z and a collision
energy slope of 3 V plus at offset of 2 V.Data analysis
The mass spectrometry raw data was processed to peak
list format by using MassHunter Qualitative Analysis
software (Agilent Technologies, Version B.03.3). These
processed peak list files were then searched against
Human RefSeq Protein Database (Release 40) containing
31,811 protein sequences through Proteome Discoverer
platform (Thermo Scientific, Version 1.2). The workflow
includes spectrum files, spectrum selector, Mascot and
Sequest search nodes followed by peptide validator for
false discovery analysis whereas a reporter ion quantifier
was used for quantitation. Search parameters included
trypsin as the enzyme with one missed cleavage allowed,
oxidation of methionine, deamidation at aspargine and
glutamine were set as a variable modification whereas
methyl-thio at cysteine and iTRAQ label at N-terminus
of the peptide and lysine were set as a fixed modifica-
tion. The reporter ion window tolerance was set at
100 ppm. The identified peptides were filtered using
1% false discovery rate derived using decoy database
search strategy and top ranked hit based on peptide
score, XCorr and IonScore for Sequest and Mascot re-
spectively. The search results from both Masoct and
Sequest were merged and unique peptide(s) identified
for each protein were used to calculate relative protein
quantitation in Proteome Discoverer workflow. The
average ratio was used for relative protein quantification
for proteins with multiple peptide matches. Bioinfor-
matic analysis was carried out to categorize proteins
based on biological processes, cellular component and
molecular function classification using annotations in
Human Protein Reference Database (HPRD, http://hprd.
org) [35], which is in compliance with gene ontology
(GO) standards.Immunohistochemical labeling
Formalin fixed and paraffin embedded autopsy tissues
were collected and cut into 4 μm thick sections on glass
slides. These slides were subjected for deparaffinization
and rehydration. Endogenous peroxidase activity was
quenched by 3% H2O2 for 20 min at room temperature.
For antigen retrieval, the tissue sections were micro-
waved in citrate buffer (pH 6.0) for 30 min. The tissue
sections were incubated with 3% skimmed milk in PBS,
pH 7.4 at room temperature. The tissue sections were
incubated with primary antibodies at following dilutions -
anti-amphiphysin (dilution 1:100, catalog # ab52646),
anti-neurofascin (dilution1:250, catalog # ab31457), anti-
ferritin light chain (dilution 1:500, catalog # ab69090)

































Figure 1 Outline of the quantitative proteomic strategy. TBM-infected and uninfected frontal cortex tissues were used to extract proteins
and subjected to digestion with trypsin. Peptides from the two groups were labeled with iTRAQ reagents followed by LC-MS/MS on a QTOF
mass spectrometer. A subset of the differentially expressed molecules were validated by immunohistochemistry.
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http://www.clinicalproteomicsjournal.com/content/9/1/12In parallel with test slides, negative and positive con-
trols were also subjected for overnight incubation at
room temperature, followed by incubation with predi-
luted secondary antibody conjugated with poly HRP
(catalog # K4011) from Dako. The reaction was visua-
lized with chromogen substrate DAB/H2O2 (Dako
catalog # K4007) as per manufacturer’s instructions.
The sections were counterstained with hematoxylin.Results and discussion
We used six TBM and six uninfected samples for our
quantitative proteomic analysis. The overall workflow
for the study is depicted in Figure 1. The tandem mass
spectra were searched against human NCBI RefSeq
release 40 (31,811 protein sequences) using Mascot and
Sequest search engines through the Proteome Discoverer
software. A total of 81,494 spectra were acquired which
resulted in 5,988 peptide-spectrum matches. We identi-
fied a total of 434 proteins with 919 unique peptides.
The protein and peptide data is provided in Additional
file 2: Table S2 and Additional file 3: Table S3, respect-
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Figure 2 Subcellular localization and biological process of differentia
process (B) of differential expressed proteins are shown.downregulated proteins at 1% FDR. The distribution of
cellular localization and biological processes of the differ-
entially expressed proteins is shown in Figure 2A and B.
The subcellular localization and biological processes of
the differentially expressed proteins were classified based
on annotations in Human Protein Reference Database
(HPRD, http://hprd.org) [35]. Partial list of differentially
expressed proteins are provided in Tables 1 and 2.Proteins previously implicated in TBM and tuberculosis
associated studies
Proteins that have previously been implicated in TBM
and tuberculosis associated studies included Vimentin
(VIM), Peroxiredoxin 5 (PRDX5), Glial fibrillary acidic
protein (GFAP), Signal-regulatory protein alpha (SIRPA)
and Protein disulfide isomerase family A, member 6
(PDIA6). VIM is an intermediate filament family protein
and is also the potential ligand for natural cytotoxicity
triggering receptor 1 (NKp46). VIM was shown to be 2.8-
fold upregulated in the present study. VIM is involved in
the lysis of the MTB-infected cells through NKp46







lly expressed proteins. Subcellular localization (A) and biological




1 WARS Tryptophanyl-tRNA synthetase, cytoplasmic
isoform b
It induced by interferon and involved in the catalyzation
of the aminoacylation of tRNA (trp) with tryptophan.
7.2
2 SLC4A4 Electrogenic sodium bicarbonate
cotransporter 1 isoform 2
It plays a functional role in the regulation of bicarbonate
secretion and absorption and intracellular pH.
6.9
3 NPM1 Nucleophosmin isoform 3 It is a phosphoprotein which shuttles between the
nucleus and the cytoplasm. It plays a role in ARF/p53
signaling pathway.
4.8
4 DHX9 ATP-dependent RNA helicase A It localizes to cytoplasm and nucleus. It acts as a
transcriptional regulator.
4.9
5 HPCA Neuron-specific calcium-binding protein
hippocalcin
It belongs to the neuron-specific calcium-binding
proteins family. It may play a role in the neurons of
the central nervous system.
4.4
6 GPM6A Neuronal membrane glycoprotein
M6-a isoform 3
It is a transmembrane protein and expressed on neurons
in the central nervous system.
3.8
7 GFAP Glial fibrillary acidic protein isoform 2 It is an intermediate filament protein and a marker for
astrocytes. It is overexpressed in astrogliosis.
3.2
8 SLC8A2 Sodium/calcium exchanger 2 precursor It is a Sodium/calcium exchanger, regulates the
intracellular calcium concentrations.
2.8
9 VIM Vimentin It belongs to the intermediate filament protein family.
It plays a role in cell shape and integrity.
2.8
10 VGF VGF nerve growth factor inducible precursor It expressed in neuroendocrine cells and overexpressed
by nerve growth factor
2.5
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expressed in MTB (H37Rv) infected mice study [38]. In
our study, it was found to be 2.2-fold overexpressed in
TBM as compared to controls. PRDX5 plays an antioxi-
dant protective role in tissues. GFAP showed 3.2-fold
upregulation in TBM as compared to controls. Our




1 PDIA6 Protein disulfide-isomerase
A6 precursor
It is endoplas
a role in foldi
2 KPNA4 Importin subunit alpha-4 It is cytoplasm
3 PFDN5 Prefoldin subunit 5 isoform alpha It belongs to
the molecular
4 GARS Glycyl-tRNA synthetase It belongs to
plays a role in
5 MDH1 Malate dehydrogenase, cytoplasmic It localized to
malate-aspart
6 AK1 Adenylate kinase isoenzyme 1 It is an enzym
composition
7 LANCL1 LanC-like protein 1 It is a loosely
belongs to th
proteins. It pla
8 SNCG Gamma-synuclein It belongs to
and it may pl
diseases.




10 NCDN Neurochondrin isoform 2 It is a cytopla
learning proc4.7-fold overexpression of GFAP at mRNA level in
TBM cases [39]. Representative MS/MS and reporter
ion spectra of differentially regulated molecules are pro-
vided in Figure 3. MS/MS spectrum of GFAP is depicted
in Figure 3A. SIRPA belongs to the signal regulatory
family. The regulation of SIRPA expression can change
the effectiveness of signaling processes. Growth factorFold-change
mic reticulum (ER) resident protein and it plays
ng of disulfide-bonded proteins
2.0
ic protein, recognizes nuclear localization signals. 2.0
the prefoldin alpha subunit family. It is a subunit of
chaperone complex, involved in protein folding.
2.5
the class II family of tRNA synthetases and this protein
autoimmune diseases.
3.0
the cytoplasm and mitochondria. It involved in
ate shuttle.
3.0
e involved in regulating the adenine nucleotide
in the cell and it is localized in the cytosol.
3.0
associated peripheral membrane protein which
e LanC family of bacterial membrane-associated
ys a role in antimicrobial peptide synthesis.
5.0
the member of the synuclein family of proteins
ay a role in the pathogenesis of neurodegenerative
5.0
endoplasmic reticulum (ER) and involved in the
f very long chain fatty acid synthesis
7.0
smic protein and may play a role in spatial
esses.
7.0
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http://www.clinicalproteomicsjournal.com/content/9/1/12receptors and growth hormone receptor signaling is sup-
pressed by the upregulation of SIRPA [40-43]. SIRPA
regulates the NFkB activity that renders the cells resist-
ant to TNF mediated apoptosis [44]. A recent study
reported SIRPA to be 2-fold upregulated at the mRNA
level in TBM [39]. In our study, also SIRPA protein was
found to be 2-fold overexpressed in TBM. Protein disul-
fide isomerase family A, member 6 (PDIA6) is a protein
that belongs to the endoplasmic reticulum (ER) and it is
involved in the folding of disulphide bonded proteins
[45]. This protein was shown to be downregulated
(2.6-fold) in TBM at the mRNA level [39] and con-
firmed to be downregulated (2.5-fold) at the protein
level in our study.
In our previous study on TBM using gene expression
microarray, we had identified 2,434 differentially regu-
lated transcripts [39]. In current proteomic study, 33 out
of 134 differentially regulated proteins were alsoQQVHVELDVAKPDLTAALK







































































































































Figure 3 Representative MS and MS/MS spectra of upregulated as we
from selected differentially expressed proteins identified in this study. Inset
protein (GFAP); (B) Amphiphysin (AMPH); (C) Neurofascin (NFASC) (D) Ferritidentified to be differentially expressed in the microarray
dataset. However, only three proteins (GFAP, SIRPA,
ACTB) were found to be correlated at both mRNA and
protein levels, which is likely due to low correlation fre-
quently observed between transcriptomic and proteomic
studies.Differentially expressed proteins with no previous
association with TBM
We identified a large number of differentially expressed
proteins, which have not been reported earlier in the lit-
erature to be associated with TBM. These novel proteins
include Ca++−dependent secretion activator 2 (CADPS2)
which belongs to the calcium-dependent activator of
secretion (CAPS) protein family, and was found 3-fold
upregulated in the present study. CADPS2 protein regu-
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ll as downregulated proteins. MS and MS/MS spectra of peptides
s shows relative intensities of reporter ions. (A) Glial fibrilllary acid
in, light chain (FTL).
Kumar et al. Clinical Proteomics 2012, 9:12 Page 8 of 13
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(AMPH) (Figure 3B) is an adapter molecule which
plays a role in synaptic vesicle endocytosis [48] and it
was found to be 3.7-fold overexpressed in TBM com-
pared to control cases. Heat shock protein 90kDa alpha
(cytosolic), class A member 1 (HSP90AA1) is a highly
conserved molecular chaperone and was found to be
2.1-fold upregulated in the present study. HSP90AA1
is a molecular chaperone, which plays a role in signal
transduction, protein degradation, protein folding and is
expressed under stress conditions and according to a re-
cent report it plays a role in gene expression in mamma-
lian cells [49]. Neurofascin (NFASC) (Figure 3C) is the
L1 family immunoglobulin cell adhesion molecule, found
to be 2-fold upregulated in the current study. NFASC
plays a role in organization of the axon initial segment
(AIS) and nodes of Ranvier in central nervous system,
neurite extension and neurite fasciculation [50-52]. Fer-
ritin, light chain (FTL) (Figure 3D) protein is an iron
storage protein which, play a role in neurodegeneration
[53] and found to be 66-fold downregulated in the
present study. Downregulation of FTL causes the depig-
mentation in metastatic melanoma cells [54] and
responds during inflammation especially where oxidative
stress and reactive oxygen intermediates are generated
[55,56].Figure 4 Immunohistochemical labeling of AMPH protein overexpres
cerebral cortex (A) shows labeling of cortical ribbon in a synaptic pattern (
pyramidal neurons (arrow, C) with synaptic pattern of neuropil labeling. TB
controls (D) with intense labeling of neuropil in grey matter (E) and pyram
C: Obj x40, F: Obj x 20] [g – grey matter, w – white matter].Validation of candidate biomarkers by
immunohistochemical labeling
We used immunohistochemistry (IHC) to validate a sub-
set of differentially expressed proteins identified in
iTRAQ-based study. The results from IHC validation of
AMPH, NFASC and FTL from fifteen TBM cases are
summarized below.
Amphiphysin (AMPH) is an adapter molecule asso-
ciated with cytoplasmic surface of the synaptic vesicle,
which was confirmed to be overexpressed in all 15 TBM
cases tested (Figure 4). AMPH protein expression was
seen diffusely distributed in synaptic fashion in the cor-
tical ribbon in control cases (Figure 4A, B). The neurons
in the grey matter showed cytoplasmic labeling with
AMPH (Figure 4C). In comparison, cases of tuberculous
meningitis revealed intense staining of the neuropil of
the cortical ribbon reflecting upregulation of protein
expression (Figure 4D, E). Several neurons showed cyto-
plasmic accumulation of protein within the neuronal
soma (Figure 4F). Astrocytes and microglia were not
labeled and white matter was devoid of labeling. Inflam-
matory exudates in the meninges in the cases of tubercu-
lous meningitis also did not reveal positivity.
Neurofascin (NFASC) is an adhesion molecule, which
plays an important role in cell communication and signal
transduction. Overexpression of this protein was validatedsed in TBM. Normal controls (A-C): Whole mount preparation of
B). Higher magnification highlights scattered strong labeling of
M (D-F): Strong labeling of the cortical ribbon seen in contrast to
idal neurons in the cortex (F). [A, D: whole mounts x10, B, E: Obj x5,
Figure 5 (See legend on next page.)
Kumar et al. Clinical Proteomics 2012, 9:12 Page 9 of 13
http://www.clinicalproteomicsjournal.com/content/9/1/12
(See figure on previous page.)
Figure 5 Immunohistochemical labeling of NFASC protein overexpressed in TBM. Normal controls (A, B): Light labeling of the cortical
ribbon (A) in the frontal cortex with synaptic pattern (B). TBM(C-G): Whole mount preparation (C) highlight the darker labeling of the cortical
ribbon and the inflammatory exudate in the subarachnoid space. The macrophages (E) entrapped in the inflammatory exudate are strongly
labeled. Glial cells (F, arrows) and linearly arranged neuronal cytoplasm (G, arrows) are strongly labeled in the grey matter. [A, C: x10, B, D: xObj.5,
E-G: xObj.20].
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http://www.clinicalproteomicsjournal.com/content/9/1/12in all 15 TBM cases. NFASC in control cases revealed
positive labeling of neuropil in cortex (Figure 5A, B) with
only occasional neurons showing cytoplasmic labeling in
the lower cortical layers. No labeling of astrocytes or
oligodendroglia was noted in control cases. In cases ofFigure 6 Immunohistochemical labeling of FTL protein downregulatio
matter (A). In the grey matter (B), the neurons (arrow) and dendritic proces
and oligodendroglial cells are stained intensely. TBM (D-F): In the grey and
contrast to control. In the subpial zones and deep grey matter beneath the
stained (E) while the neuropil and neurons are less intense. Microglial cells
[A, D: whole mountsx10, B, C: xObj.20, E: xObj.x5, F: xObj.20].tuberculous meningitis, intense labeling was seen in
the neuropil of grey matter in synaptic fashion reflecting
upregulated expression of protein (Figure 5C, D). Several
small granule neurons expressed cytoplasmic positivity in
the upper cortical layers close to the surface exudatesn in TBM. Normal controls (A-C): Intense labeling of grey and white
ses are intensely labeled (B) while in the white matter (C), neuropil
white matter of the frontal cortex, showed very light labeling in
exudate and the inflammatory cells in the subarachnoid space are
in white matter and perivascular zones show labeling (F).
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subpial astrocytes beneath the surface exudates ex-
pressed NFASC protein in cytoplasm extending into its
branching processes (Figure 5F), in addition to macro-
phages in the inflammatory exudates in the subarachnoid
space (Figure 5E).
Ferritin light chain (FTL) is an intracellular iron stor-
age protein and downregulation of this protein was vali-
dated by IHC in 15 TBM cases (Figure 6). Expression of
this protein was observed in control cases within the grey
and white matter (Figure 6A), with grey matter showing
higher intensity of expression compared to white matter.
In the grey matter, neurons revealed intense labelling
of the cytoplasm while dendritic processes in neuropil
also revealed strong labelling (Figure 6B). In the white
matter, oligodendroglial cells expressed the protein in
its cytoplasm in addition to neuropil showing positivity
(Figure 6C). In cases of tuberculous meningitis, marked
down regulation of protein expression was seen in con-
trast to the normal cortex (Figure 6D). Interestingly,
while neuronal expression was markedly downregulated,
labelling was seen in microglial cells ensheathing neurons,
as also in subpial and perivascular astrocytes seen below
the inflammatory exudates in the subarachnoid spaces
(Figure 6E). In the white matter, neuropil and perivascular
microglia revealed protein expression in the branching
ramified processes of activated miciroglia (Figure 6F).Public availability of proteomic data
We have submitted the peptide data to Human Proteinpedia
(http://www.humanproteinpedia.org) [57] and raw data files
to Tranche data repository (https://proteomecommons.org/
tranche/) for easy access to the research community. The





The combination of mass spectrometry and quantitative
proteomics is being increasingly utilized for discovering
potential biomarkers. In the current study, using an
iTRAQ-based quantitative proteomic approach, we were
able to identify several known and novel molecules that
are differentially expressed in TBM. We validated the
expression levels of three novel biomarker candidates -
AMPH, NFASC and FTL - by IHC on brain tissue
sections from TBM cases as well as controls. These
promising candidate markers warrant further evaluation
in CSF from TBM patients to determine their clinical
utility.Additional files
Additional file 1: Table S1. List of TBM and control samples used in
the present study.
Additional file 2: Table S2. A complete list of Proteins identified in
TBM.
Additional file 3: Table S3. A complete list of peptides identified in
TBM.
Abbreviation
CSF: Cerebrospinal fluid; TBM: Tuberculous meningitis; iTRAQ: Isobaric tag for
relative and absolute quantitation; QTOF: Quadrupole Time-of-Flight;
IHC: Immunohistochemistry; TCEP: Tris (2-carboxyethyl) phosphine;
MMTS: Methyl-methanethiosulfonate; TEAB: Triethylammonium bicarbonate
buffer; ACN: Acetonitrile; Poly-HRP: Polymer conjugate of horseradish
peroxidase; DAB-3: 3-Diaminobenzidine; HPLC: High performance liquid
chromatography; SCX: Strong cation exchange; FDR: False discovery rate.
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